Efficacy of 851B Gel for Treating High-Risk Cervical Human Papillomavirus Infection in Women.

ClinicalTrials.gov ID: NCT00117884

Public ClinicalTrials.gov record NCT00117884. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Jul 22, 2026, 7:34 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Double-blind, Placebo-Controlled, Dose Response Study to Evaluate 851B Gel Delivered Intravaginally Twice a Week for Two, Three-Week Cycles in Women Who Are Positive For High-Risk Genotypes of Human Papillomavirus and Have Mild Cytological Abnormalities

Study identification

NCT ID: NCT00117884
Recruitment status: Terminated
Study type: Interventional
Phase: Phase 2
Lead sponsor: Takeda; Industry
Enrollment: 240 participants

Conditions and interventions

Conditions

Papillomavirus Infections

Interventions

851B Drug

Drug

Eligibility (public fields only)

Age range: 18 Years to 40 Years
Sex: Female
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Mar 31, 2006
Primary completion: May 31, 2008
Completion: May 31, 2008
Last update posted: Aug 18, 2016

2006 – 2008

United States locations

U.S. sites: 22
U.S. states: 14
U.S. cities: 22

Facility	City	State	ZIP	Site status
Not listed	Colton	California	92324	—
Not listed	San Diego	California	92108	—
Not listed	Colorado Springs	Colorado	80910	—
Not listed	Boynton Beach	Florida	33461	—
Not listed	Tampa	Florida	33607	—
Not listed	Augusta	Georgia	30912	—
Not listed	Savannah	Georgia	31405	—
Not listed	Louisville	Kentucky	40202	—
Not listed	Detroit	Michigan	48201	—
Not listed	Moorestown	New Jersey	08057	—
Not listed	New York	New York	10032	—
Not listed	Charlotte	North Carolina	28203	—
Not listed	Winston-Salem	North Carolina	27103	—
Not listed	Oklahoma City	Oklahoma	73104	—
Not listed	Pittsburgh	Pennsylvania	15213	—
Not listed	Nashville	Tennessee	37203	—
Not listed	Arlington	Texas	76012	—
Not listed	Austin	Texas	78705	—
Not listed	Houston	Texas	77004	—
Not listed	Renton	Washington	98055	—
Not listed	Seattle	Washington	98105	—
Not listed	Spokane	Washington	99207	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT00117884, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Aug 18, 2016 · Synced Jul 22, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00117884 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →